Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update

J Cereb Blood Flow Metab. 2020 Sep;40(9):1752-1768. doi: 10.1177/0271678X20923551. Epub 2020 May 19.

Abstract

Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality and disability but no specific or effective treatment. In the last two decades, much has been learned about the pathologic mechanisms of ICH. It is now known that after ICH onset, immune and inflammatory responses contribute to blood-brain barrier disruption, edema development, and cell death processes, jointly resulting in secondary brain injury. However, the translation of potential therapies from preclinical to clinical success has been disappointing. With the development of new laboratory technology, recent progress has been made in the understanding of ICH pathomechanisms, and promising therapeutic targets have been identified. This review provides an update of recent progress on ICH and describes the prospects for further preclinical studies in this field. Our goal is to discuss new therapeutic targets and directions for the treatment of ICH and promote the effective transformation from preclinical to clinical trials.

Keywords: Intracerebral hemorrhage; immune interventions; inflammation; microglia; secondary injury.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Blood-Brain Barrier / pathology
  • Cerebral Hemorrhage / complications*
  • Cerebral Hemorrhage / therapy*
  • Clinical Trials as Topic
  • Encephalitis / etiology*
  • Encephalitis / therapy*
  • Humans
  • Macrophages